{"denoms":[{"counts":[{"groupId":"BG000","value":"44"}],"units":"Participants"}],"groups":[{"description":"Eltrombopag (Promacta): Subjects commenced eltrombopag at a dose of 50 mg, which was increased by 25 mg every 2 weeks if the platelet count had not increased by 20 × 103/µL, to a maximum dose of 150 mg.","id":"BG000","title":"Eltrombopag"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"27"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"13"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"19"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"25"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"33"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"11"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"21"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"8"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}],"populationDescription":"Note that baseline information was available on the 44 patients consented and enrolled, but one patient was removed from protocol before initiation of the investigative agent, and thus adverse events and results information refers only to 43 patients"}